{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "AKTS", "name": "Aktis Oncology, Inc.", "url": "https://frontierpicks.com/dossiers/AKTS/", "json_url": "https://frontierpicks.com/dossiers/AKTS.json", "status": "DORMANT", "current_conviction": "MEDIUM", "graded_conviction": null, "archetype": { "code": "a1", "n": 1 }, "current_thesis": "The \"coverage is spent\" read broke: Wedbush ($35) and BMO ($37) initiated Outperform on 2026-08-19, taking the cohort to five, and the 2026-08-13 Q2 reaffirmed Q1 2027 AKY-1189 data with $517.3M cash. Price did not follow — $24.07 on 2026-08-21 versus $24.13 on 2026-08-07. Sponsorship rebuilt into a flat tape; no dated catalyst before Q3 results.", "invalidation_trigger": "A weekly close below $22 breaks the range built off the 2026-07-30 low print of $22.39 and says the 2026-08-19 initiations failed to clear post-lock-up supply; secondarily, any of the five covering houses cutting a target below $30, or the Q3 print hedging Q1 2027 NECTINIUM-2 timing.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "oncology-immunology", "precision-biotech-therapeutics", "rare-disease-gene-therapy" ], "tags": [], "sources": [], "notes": [ "Ticker disambiguation: AKTS = Aktis Oncology (radiopharma, IPO Jan 2026), not the defunct Akoustis Technologies. A semiconductor theme tag on this ticker is a data error.", "Pre-revenue apart from Lilly collaboration revenue recognised cost-incurred. No clinical efficacy data until Q1 2027 (AKY-1189 NECTINIUM-2 Phase 1b preliminary).", "Eli Lilly holds a $100M IPO anchor (~one-third of shares sold) plus an up-to-$1.1B collaboration; LLY radiopharma headlines read through to AKTS.", "The ~180-day IPO lock-up (est. ~2026-07-07 to 07-11) is elapsed; insider Form 4 flow is a continuing supply variable, not a one-day event.", "Cash and marketable securities $517.3M at 2026-06-30, guided to fund the operating plan into 2029 — no scheduled dilution event before the 2027 readouts.", "Actinium-225 supply is a modality-wide manufacturing bottleneck affecting every listed RLT developer, not an Aktis-specific issue." ], "body_markdown": "## Current Thesis\n\nTwo dated events since the last update changed the shape of this read. On 2026-08-13 Aktis reported Q2 2026: collaboration revenue $3.4M against $1.6M a year earlier, net loss $24.1M against $18.1M, R&D $25.3M against $18.6M, and cash, cash equivalents and marketable securities of $517.3M at 2026-06-30 versus $226.8M at year-end 2025. The release reaffirmed preliminary AKY-1189 Phase 1b data from NECTINIUM-2 in the first quarter of 2027 and kept the \"into 2029\" operating-plan language. Six days later, on 2026-08-19, Wedbush initiated Outperform with a $35 target and BMO Capital initiated Outperform with a $37 target, taking the covering cohort from three houses to five. The earlier read — that sell-side sponsorship had stopped expanding after J.P. Morgan's 2026-07-14 maintain at $33 — no longer holds.\n\nWhat did not move is the price. The 2026-08-21 close was $24.07; on 2026-08-07 it was $24.13. Two fresh Outperform initiations at $35 and $37 landed in between and the tape is flat across the stretch. Two sessions is far too short a window to call that a rejection, and it should not be graded as one. It is, however, the single observable that separates this from a working re-rating: new institutional sponsorship is arriving and is being absorbed rather than chased.\n\nThe narrative leg on offer is unchanged in substance — the newest US-listed radioligand-therapy (RLT) pure-play, Actinium-225-conjugated miniproteins against two clinically validated solid-tumour antigens (Nectin-4, B7-H3), with Eli Lilly as anchor holder and collaboration partner and no financing event scheduled ahead of the data. What an investor is buying between now and Q1 2027 is sponsorship and platform analogy. There is no efficacy datapoint in the interval.\n\nThe narrative is **maturing**. Dating it: the 2026-08-19 double initiation is new participation, which rules out saturated's thin-new-bid condition; the 2026-06-30 all-time closing high of $32.23 has not been retested and the 2026-08-21 close of $24.07 sits roughly a quarter below it, which rules out accelerating; the 2026-08-13 reaffirmation of Q1 2027 timing and the $517.3M cash balance rule out dead. Well known, still working, flow moderating.\n\n## Bull Case\n\n- Coverage cohort doubled in size in ten weeks and every published rating is Buy-equivalent: HC Wainwright Buy $35 (2026-06-02), Raymond James Strong Buy $40 (2026-06-16), J.P. Morgan Overweight $33 (2026-07-14), Wedbush Outperform $35 (2026-08-19), BMO Capital Outperform $37 (2026-08-19). The published target band spans $33 to $40 against a 2026-08-21 close of $24.07.\n- Wedbush's David Nierengarten framed the initiation on 2026-08-19 around a \"compelling pure-play radiopharma story\" targeting two clinically validated antigens with limited direct radioconjugate competition — a competitive-set argument, not a beta argument.\n- Financing risk is off the table through the readouts: $517.3M cash and marketable securities at 2026-06-30, guided to fund the operating plan into 2029. That is a rising balance versus $226.8M at year-end 2025, reflecting the January 2026 IPO at $18.00.\n- The Q2 release put three dated operational items on the board rather than one: Phase 1b BActinium-2 basket trial in lung and other B7-H3 tumours to commence in 2H 2026, an in-house GMP facility operational in 2H 2026, and two early programs tracking to development-candidate nomination and IND-enabling activities in Q1 2027.\n- Collaboration revenue of $3.384M beat the $2.000M consensus estimate at the 2026-08-13 print — small in absolute terms and recognised on a cost-incurred method against the Lilly research collaboration, but it is the only line on the P&L that beat.\n\n## Bear Case\n\n- Burn is accelerating on every line. Q2 net loss $24.1M versus $18.1M in Q2 2025; R&D $25.3M versus $18.6M; G&A $7.0M versus $3.9M — G&A close to doubled year-over-year in the first full post-IPO quarter. Q2 EPS of -$0.44 missed the -$0.43 estimate.\n- Cash fell from $538.5M at 2026-03-31 to $517.3M at 2026-06-30. The \"into 2029\" language is guidance, and it is being carried against a rising quarterly loss.\n- July's post-lock-up Form 4 flow is documented and is the supply the market has to clear: CMO Akos Czibere exercised 50,000 options at $4.95 and sold 50,000 shares on 2026-07-08; COO Shulamit Ron-Bigger sold across three transactions the same day for a reported $1,387,557;\n- The gap to the first fundamental datapoint is now about five months. Nothing between 2026-08-22 and the Q1 2027 NECTINIUM-2 preliminary readout prices the platform on clinical evidence; the Q3 print, due around early November, is another cash-and-pipeline update on a pre-revenue company.\n- The newest work is not the most aggressive work.\n\n## Setup & Price Structure\n\nThe 2026-08-21 close was $24.07, with the shares up 18.3% over three months and RSI(14) at 63.7 — up from 51.1 on 2026-08-07 at a near-identical price, meaning the recovery came through shrinking down-moves rather than a fresh advance. The structure since the 2026-06-30 closing high of $32.23 is a $22–$25 range: the low print on record in that range is $22.39 on 2026-07-30, and the 52-week range was $14.72–$34.19 as of 2026-08-07. The January 2026 IPO priced at $18.00.\n\nPositioning observables, stated without a verdict attached: five covering houses, no published sell rating, and public consensus aggregators showing an average 12-month target of $34.38 as of 2026-08-07 — before the two 2026-08-19 initiations. Three insiders sold in the July post-lock-up window; the lock-up (estimated ~2026-07-07 to 07-11) is elapsed, so Form 4 flow is a continuing variable rather than a single event. There is no earnings date inside 30 days. The statutory Q2 13F deadline passed on 2026-08-14, which makes institutional register composition a checkable item rather than an assumption. No secondary offering or shelf takedown has been announced; with $517.3M on hand and 2029 runway guidance, issuance into strength is not the near-term supply channel — insider sales are.\n\nThe structural question the range answers is narrow: whether $22–$25 is a base built under new sponsorship or a distribution shelf where IPO allocation exits. The 2026-08-19 initiations argue the first; the flat price response argues nothing yet either way.\n\n## Catalyst Calendar (next 30 days)\n\n- **No confirmed company-scheduled event between 2026-08-22 and 2026-09-21.** Stating that plainly is the honest version of this section. Aktis presented at the BofA Securities Health Care Conference on 2026-05-13 and the Jefferies Global Healthcare Conference on 2026-06-03; as of 2026-08-22 no September 2026 conference appearance has been announced.\n- **~2026-09-30 (est.)** — rolling post-lock-up Form 4 flow. July produced three selling insiders; the disclosure channel is continuous and each filing is same-week observable.\n- **~2026-10-31 to 2026-12-31 (est.)** — commencement of the Phase 1b BActinium-2 basket trial and the in-house GMP facility becoming operational, both guided to 2H 2026 at the 2026-08-13 print.\n- **~2026-11-10 (est.)** — Q3 2026 results. Checkpoints: whether quarterly net loss exceeds Q2's $24.1M, whether \"into 2029\" survives, whether Q1 2027 NECTINIUM-2 timing survives.\n- **~2027-Q1 (est.)** — AKY-1189 NECTINIUM-2 Phase 1b preliminary data. The first event that prices the platform on clinical evidence.\n\n## What Would Change Our Mind\n\nThe structure that has to hold is the $22–$25 range that formed after the 2026-07-30 low print of $22.39. A weekly close below $22 would say that the 2026-08-19 sponsorship additions failed to clear post-lock-up supply, and that the clearing price is being set below the range rather than inside it — the same conclusion the earlier read reached, arrived at against better fundamental disclosure.\n\nThe other three conditions that would break the constructive case, in order of how quickly they become observable: any of the five covering houses (J.P. Morgan $33, HC Wainwright $35, Wedbush $35, BMO $37, Raymond James $40) publishing a target below $30 or a rating step-down, since voluntarily maintained sell-side work is the only fundamental support until 2027; a Q3 print that removes or hedges the Q1 2027 NECTINIUM-2 language; and a Q3 net loss materially above Q2's $24.1M with the \"into 2029\" runway wording dropped, which would reopen a dilution question the balance sheet currently closes.\n\nThe upside condition worth naming for symmetry: a weekly close above $32.23 would take out the 2026-06-30 all-time closing high and reclassify the leg as accelerating rather than maturing.\n\n## Correlation Notes\n\n- **Eli Lilly (LLY)** is the closest single-name read-through: $100M IPO anchor (roughly one-third of shares sold in the January 2026 offering) plus an up-to-$1.1B research collaboration whose revenue Aktis recognises on a cost-incurred method — $3.4M of it in Q2 2026. LLY radiopharma strategy headlines move sentiment here directly.\n- **Novartis / Pluvicto** sets the commercial reference for the whole RLT modality. A guide-down there compresses the multiple every listed developer trades on, Aktis included.\n- **The RLT takeout cohort** — BMS/RayzeBio ($4.1B, 2024), AstraZeneca/Fusion, Lilly/Point Biopharma — is the strategic-bid argument embedded in the sell-side targets. Deal news in the group reprices the group.\n- **Actinium-225 supply** is a modality-wide manufacturing constraint, not an Aktis-specific one; the 2H 2026 in-house GMP facility is the company's own answer to it, and a slip past year-end reads across to trial-expansion timing.\n- **Feed hygiene:** the 2026-08-14 headline grouping AKTS into an \"AI buildout\" stock list is a ticker-mismatch artifact with the defunct Akoustis Technologies, which formerly used this symbol. Any semiconductor correlation attributed to AKTS is a data error, not a relationship.", "first_seen": "2026-06-28", "last_analyzed": "2026-08-22T10:24:09+00:00", "last_synthesized": "2026-08-22", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }